Growth factors as therapeutics for diabetic neuropathy
- PMID: 18220712
- DOI: 10.2174/138945008783431727
Growth factors as therapeutics for diabetic neuropathy
Abstract
There has been a rapid growth in appreciation of the diverse array of neurotrophic factors, growth factors and other biological molecules that have the capacity to support adult neurons and direct reparative processes after injury to the nervous system. Understanding the mechanisms by which these factors operate offers the opportunity to use either the factors themselves or other agents that manipulate relevant signal transduction pathways as therapeutics for a wide range of neurodegenerative diseases, including diabetic neuropathy. In this review, we aim to summarize current knowledge of the extent to which loss of neurotrophic support contributes to the pathogenesis of diabetic neuropathy, present pre-clinical evidence that supports the potential efficacy of growth factors or their mimetics against indices of diabetic neuropathy and highlight the emerging approaches to manipulating neuronal support mechanisms that show potential for translation to clinical use. Recent advances in directly assessing the progression of nerve damage in diabetic patients will hopefully facilitate renewed clinical evaluation of treatments for degenerative diabetic neuropathy and provide the framework for advancing the potential of growth factors as a therapy for this widespread and currently untreatable condition.
Similar articles
-
Diabetic neuropathy and nerve regeneration.Prog Neurobiol. 2003 Mar;69(4):229-85. doi: 10.1016/s0301-0082(03)00034-0. Prog Neurobiol. 2003. PMID: 12757748 Review.
-
Neurotrophic factors and diabetic peripheral neuropathy.Eur Neurol. 1999;41 Suppl 1:27-34. doi: 10.1159/000052077. Eur Neurol. 1999. PMID: 10023126 Review.
-
Neurotrophins and other growth factors in diabetic neuropathy.Semin Neurol. 1996 Jun;16(2):153-61. doi: 10.1055/s-2008-1040971. Semin Neurol. 1996. PMID: 8987129 Review.
-
The role of growth factors in diabetic peripheral neuropathy.J Peripher Nerv Syst. 2004 Mar;9(1):26-53. doi: 10.1111/j.1085-9489.2004.09105.x. J Peripher Nerv Syst. 2004. PMID: 14871451 Review.
-
Neurotrophic factors in the therapy of diabetic neuropathy.Am J Med. 1999 Aug 30;107(2B):34S-42S. doi: 10.1016/s0002-9343(99)00011-x. Am J Med. 1999. PMID: 10484043 Review.
Cited by
-
Emerging therapy for diabetic neuropathy: cell therapy targeting vessels and nerves.Endocr Metab Immune Disord Drug Targets. 2012 Jun;12(2):168-78. doi: 10.2174/187153012800493486. Endocr Metab Immune Disord Drug Targets. 2012. PMID: 22236028 Free PMC article. Review.
-
Sensory neuronal sensitisation occurs through HMGB-1-RAGE and TRPV1 in high-glucose conditions.J Cell Sci. 2018 Jul 26;131(14):jcs215939. doi: 10.1242/jcs.215939. J Cell Sci. 2018. PMID: 29930087 Free PMC article.
-
Differential expression of neuregulin-1 isoforms and downregulation of erbin are associated with Erb B2 receptor activation in diabetic peripheral neuropathy.Acta Neuropathol Commun. 2013 Jul 17;1:39. doi: 10.1186/2051-5960-1-39. Acta Neuropathol Commun. 2013. PMID: 24252174 Free PMC article.
-
Vascular endothelial growth factor gene transfer for diabetic polyneuropathy.Ann Neurol. 2009 Apr;65(4):362-4. doi: 10.1002/ana.21686. Ann Neurol. 2009. PMID: 19399844 Free PMC article. No abstract available.
-
Recent mass spectrometry-based techniques and considerations for disulfide bond characterization in proteins.Anal Bioanal Chem. 2018 Apr;410(10):2467-2484. doi: 10.1007/s00216-017-0772-1. Epub 2017 Dec 18. Anal Bioanal Chem. 2018. PMID: 29256076 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical